Chronic administration of MK-801 and the NMDA receptor: further evidence for reduced sensitivity of the primary acceptor site from studies with the cortical wedge preparation.
Cortical slices removed from rats pre-treated with MK-901 0.5 mg kg-1 twice a day for 7 days had reduced responses to N-methyl-D-aspartate (NMDA) relative to quisqualate and glutamate compared with control animals. Potencies of competitive (CPMP) and non-competitive (ketamine) NMDA antagonists appeared unchanged. These changes are consistent with a reduced density of NMDA receptors.
Beart
P M
PM
University of Melbourne, Austin Hospital, Heidelberg, Victoria, Australia.
Lodge
D
D
D000818:Animals; D001667:Binding, Competitive / Q000187:drug effects; D002540:Cerebral Cortex / Q000187:drug effects / Q000378:metabolism*; D016291:Dizocilpine Maleate / Q000494:pharmacology*; D005971:Glutamates / Q000494:pharmacology; D066298:In Vitro Techniques; D008297:Male; D016202:N-Methylaspartate / Q000494:pharmacology; D016318:Quisqualic Acid / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D016194:Receptors, N-Methyl-D-Aspartate / Q000378:metabolism*
D005971:Glutamates; D016194:Receptors, N-Methyl-D-Aspartate; D016202:N-Methylaspartate; D016291:Dizocilpine Maleate; D016318:Quisqualic Acid